Citations

Clear

912 citation(s) found for "Yu, Caroline".

Enhancing Care: Caring for Transgender and Gender Diverse Patients in the Emergency Department
Brown, Caitlin S. , Schofield, Kyle , Sunga, Kharmene , Olswold, Tiffany, Herndon, Justine , Roe, Keith, Davidge‐Pitts, Caroline , Engstrom, Kellyn , Fonseca, Fi

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | October 3, 2025 | Volume: 8 | Issue: 11 | Pages: 1175-1186

10.1002/jac5.70122 Get It

ABSTRACT Transgender and gender diverse (TGD) individuals face minority stress and often avoid the emergency department (ED) due to previous negative experiences. The goal of this review is to prepare the emergency medicine pharmacist to care for TGD patients, with the ultimate goal of improving the care TGD patients receive. This review summarizes interactions with TGD patients, trauma‐informed considerations, physical exam and organ inventory sensitivities, and gender‐affirming hormone therapy and complications that may arise and be seen in the ED. Additionally, this review discusses common complaints and considerations that may commonly arise when caring for TGD patients.
Physical activity and molecular subtypes of colorectal cancer: a pooled observational analysis and Mendelian randomization study
Chalitsios, Christos V. , Markozannes, Georgios , Aglago, Elom K. , Berndt, Sonja I., Buchanan, Daniel D. , Campbell, Peter T. , Chan, Andrew T. , Dimou, Niki , Drew, David A. , French, Amy J. , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B., Harrison, Tabitha A. , Hullar, Meredith A.J. , Huyghe, Jeroen R. , Newton, Christina C. , Schmit, Stephanie L. , Steinfelder, Robert S. , Ugai, Tomotaka, Zaidi, Syed Hassan Ejaz , Woods, Michael O. , Andreson, Laura, Peters, Ulrike , Phipps, Amanda I , Tsilidis, Konstantinos K, Berndt, Sonja I , Cao, Yin , Chan, Andrew T , Dimou, Niki , Drew, David A , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B , Harrison, Tabitha A , Hoffmeister, Michael , Hsu, Li , Huang, Wen-Yi , Hullar, Meredith A , Huyghe, Jeroen R , Lynch, Brigid M , Moreno, Victor , Newton, Christina C , Nowak, Jonathan A , Obón-Santacana, Mireia , Ogino, Shuji , Schmit, Stephanie L , Steinfelder, Robert S , Sun, Wei , Thomas, Claire E , Toland, Amanda Ewart , Trinh, Quang M , Ugai, Tomotaka , Um, Caroline Y , Van Guelpen, Bethany , Schoen, Robert E , Woods, Michael O , Brenner, Hermann , Anderson, Laura , Pellatt, Andrew J , Phipps, Amanda I , Tsilidis, Konstantinos K , Buchanan, Daniel D , Campbell, Peter T , Aglago, Elom K , Markozannes, Georgios , Berndt, Sonja I. , Gunter, Marc J. , Hoffmeister, Michael , Huang, Wen‐Yi , Moreno, Vı́ctor , Murphy, Neil , Nowak, Jonathan A. , Obón‐Santacana, Mireia , Qu, Conghui , Sun, Wei , Thomas, Claire E. , Trinh, Quang M. , Um, Caroline Y. , Guelpen, Bethany Van , Schoen, Robert E. , Brenner, Hermann , Pellatt, Andrew J. , Tsilidis, Konstantinos K.

Mayo Clinic

JNCI Cancer Spectrum | September 29, 2025 | Volume: 9 | Issue: 6 | Pages: No page available

10.1093/jncics/pkaf095 | PMID 41031512 Get It

Abstract Background Physical activity is associated with lower colorectal cancer (CRC) risk, but its association with molecular subtypes defined by genetic and epigenetic alterations of the disease is unclear. Such information may enhance the understanding of the mechanisms related to the benefits of physical activity. Methods Pooled observational (cases: n = 5386; controls: n = 6798; studies n = 5) and genome-wide association data (cases: n = 8178; controls: n = 10 472; studies n = 5) were used. We used multivariable logistic regression models and Mendelian randomization to assess the association between physical activity and the risk of CRC subtypes defined by individual tumor markers (and marker combinations), namely microsatellite instability status, CpG island methylator phenotype status, and BRAF and KRAS mutations. We used case-only analysis to test for differences between molecular subtypes. We applied Bonferroni correction to account for multiple tests. Results In the pooled observational analysis, higher levels of physical activity were associated with lower CRC risk (Obs-per 1SD, odds ratio [OR] = 0.94, 95% confidence interval [CI] = 0.90 to 0.97), with an association that was stronger in males (Obs-per 1SD, OR = 0.91, 95% CI = 0.87 to 0.96) than in females (Obs-per 1SD, OR = 0.97, 95% CI = 0.91 to 1.03; Pinteraction = .04). Higher physical activity was associated with a lower risk of CRC across all molecular subtypes, especially in males. There was no difference in the associations by subtypes by pooled observational or Mendelian randomization analyses. The findings did not differ by study design, anatomical site, and early or late age onset of CRC. Conclusions Our findings suggest that physical activity is not differentially associated with the 4 major molecular subtypes involved in colorectal carcinogenesis, indicating that its benefits extend broadly across colorectal cancer pathogenesis.
Abstract B094: Ketogenic Diet Modulates Gut Microbiome Composition and Enhances Treatment Response in Patients with Advanced Pancreatic Cancer: A Phase II Study
Lee, Keehoon, Cridebring, Derek , Jameson, Gayle , Roe, Denise J. , Borazanci, Erkut , Hanna, Diana L. , ROBERTS, CAROLINE G.P. , Pelster, Meredith , Frank, Richard C. , Alistar, Angela , Miller, Alan M. , Wiedmeier, Julia E. , Algaze, Sandra , Zoller, Alison R., Hallberg, Sarah J. , Wertheim, Betsy C. , Gately, Stephen, Keppler, Jennifer, Sharma, Sunil , Rasco, Drew , Hoff, Daniel D. Von, Wiedmeier-Nutor, Julia E , Borazanci, Erkut , Lee, Keehoon , Roberts, Caroline G. P. , Rabinowitz, Joshua D.

Mayo Clinic

Cancer Research | September 28, 2025 | Volume: 85 | Issue: 18_Supplement_3 | Pages: B094-B094

10.1158/1538-7445.pancreatic25-b094 Get It

Abstract Introduction: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with limited treatment options and poor survival. This study explores how a medically supervised ketogenic diet (MSKD) impacts the gut microbiome and treatment response in patients with newly diagnosed metastatic PDAC receiving gemcitabine, nab-paclitaxel, and cisplatin chemotherapy. Methods: As part of a randomized Phase II trial, 32 evaluable patients (median age 65.9 years; 53% male), 16 were randomized to either MSKD or standard diet (SD) combined with chemotherapy. Stool samples were collected from 4 patients in the MSKD group (13 samples) and 8 patients in the SD group (23 samples). Deep shotgun metagenomic sequencing was conducted using NovaSeq (Illumina). Taxonomical and functional microbiome characterization was performed using MetaPhlAn 4.0 and HUMAnN 3.6 (The Huttenhower Lab, Harvard). Comprehensive bioinformatics analyses, using QIIME2, were performed to analyze microbiome composition and function over time. Results: Patients in the MSKD group showed better treatment responses overall. Microbiome profiles between the two groups remained distinct throughout therapy. Though not statistically significant due to sample size, MSKD patients showed lower alpha diversity (Shannon diversity; p-value=0.1339), likely reflecting reduced intake of fermentable fiber. Differential abundance analysis using the ANCOM-BC method revealed a significant enrichment of beneficial taxa in the MSKD group compared to the SD group (p<0.05, log-fold change [lfc]≥2), including Akkermansia muciniphila (linked to improved response to immune checkpoint inhibitors; p=0.017931, q=1), Intestinimonas butyriciproducens (a short-chain fatty acid [SCFA] and butyrate producer; p=3.09E-05, q=0.017), and Streptococcus thermophilus (a supporter of gut mucosal health; p=1.15E-05, q=0.006). During the course of the study, only MSKD patients showed sustained increases in Roseburia hominis (SFCA/butyrate producer; p=3.94E-05, q=0.021) and Lacticaseibacillus rhamnosus (with anti-inflammatory and immune-modulating properties; p=7.28E-19, q=3.98E-16), along with a marked reduction in potentially pro-inflammatory Actinomyces spp.(p≤4.47E-05, q≤0.024). Functional profiling showed increased abundance of cancer-relevant microbial pathways in MSKD patients, including phosphatidate metabolism (PWY-7039; involved in lipid signaling and immune regulation; p=4.36E-04, q=0.20) and allantoin degradation (PWY-5705; linked to redox balance; p=9.16E-06, q=0.004). Conversely, L-ascorbate biosynthesis V (PWY-6415) was reduced (p=3.80E-04, q=0.17), likely due to decreased D-galacturonate substrate availability from fiber restriction. Conclusion: These findings suggest that an MSKD may beneficially modulate the gut microbiome in ways that support and enhance therapeutic response in patients with PDAC. Further validation in a larger cohort is warranted to confirm these results and improve analytical resolution. Citation Format: Keehoon Lee, Derek Cridebring, Gayle S. Jameson, Denis J. Roe, Erkut Borazanci, Diana L. Hanna, Caroline G.P. Roberts, Meredith S. Pelster, Richard C. Frank, Angela T. Alistar, Alan M. Miller, J. Erin Wiedmeier-Nutor, Sandra D. Algaze, Alison R. Zoller, Sarah J. Hallberg, Betsy C. Wertheim, Joshua D. Rabinowitz, Stephen Gately, Jennifer Keppler, Sunil Sharma, Drew W. Rasco, Daniel D. Von Hoff. Ketogenic Diet Modulates Gut Microbiome Composition and Enhances Treatment Response in Patients with Advanced Pancreatic Cancer: A Phase II Study [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_3):Abstract nr B094.
Overcoming hepatic artery variations: Arterial reconstruction strategies to expand normothermic machine perfusion in liver transplantation
Ohara, Stephanie, Li, Xingjie , Ruch, Brianna , Nunez-Nateras, Raphael, Cosentino, Christopher P., Mirie, Kayla R., Hewitt, Winston R. , Harbell, Jack W. , Singer, Andrew L., Moss, Adyr A. , Reddy, Kunam S. , Mathur, Amit K. , Nunez-Nateras, Raphael, Zhang, Nan , Katariya, Nitin , Jadlowiec, Caroline C. , Nguyen, Michelle

Mayo Clinic

Liver Transplantation | September 26, 2025 | Volume: 32 | Issue: 6 | Pages: 812-822

10.1097/lvt.0000000000000741 | PMID 41002214 Get It

Normothermic machine perfusion (NMP) enables preservation and functional assessment of liver allografts, improving outcomes, particularly in marginal organs. However, the TransMedics Organ Care System (OCS) permits only single hepatic artery (HA) cannulation, limiting its use in grafts with variant arterial anatomy. Arterial reconstruction before NMP may overcome this limitation and expand the pool of grafts eligible for perfusion. We conducted a retrospective single-center cohort study of adult liver transplants utilizing OCS from January 2022 to September 2024. Allografts with variant hepatic artery anatomy requiring arterial reconstruction before NMP initiation were identified. Postoperative outcomes, including vascular and biliary complications, were compared between reconstructed and non-reconstructed grafts. Among 541 OCS-preserved grafts, 74 (13.7%) underwent arterial reconstruction. Compared with non-reconstructed grafts, reconstructed grafts had longer cross-clamp to cannulation time (2.8 vs. 2.4 h, p <0.001), but similar rates of early allograft dysfunction (23.0% vs. 20.8%, p =0.65), ischemic cholangiopathy (4.1% vs. 4.1%, p =1.00), and primary nonfunction (0.0% vs. 0.4%, p =1.00). Early (2.7% vs. 0.2%, p =0.05) and late hepatic artery thrombosis (HAT) (4.1% vs. 2.1%, p =0.40) were infrequent and not significantly different between non-reconstructed and reconstructed groups, respectively. Hepatic artery stenosis occurred more often in reconstructed grafts (12.2% vs. 4.1%, p =0.008), though most cases were managed with interventional radiology or surgical revision. Only one reconstructed graft required retransplantation due to vascular complications. Arterial reconstruction before NMP is safe and feasible, enabling successful perfusion and transplantation of liver allografts with variant HA anatomy. These findings support the broader application of NMP in anatomically complex donor livers.
Early Removal of Ureteral Stents When Attached to the Foley Catheter in Living Donor Kidney Transplant Recipients Reduces Urinary Tract Infections
Lam, Jenny , Mahgoub, Mohammed, Kesik, Esma, Smith, Byron H. , Ovdat, Esther , Rebolledo, Patricia , Bunn, Weslyn, Reddy, Kunam S. , Perry, Dana K. , Prieto, Mikel , Nyberg, Scott L. , Elali, Ibrahim, Kesik, Esma , Smith, Byron , Jadlowiec, Caroline , Mao, Shennen, Perry, Dana, Bentall, Andrew , Schinstock, Carrie , Nyberg, Scott, Stegall, Mark D , Elali, Ibrahim , Jadlowiec, Caroline C. , Mao, Shennen A. , Bentall, Andrew , Schinstock, Carrie A. , Stegall, Mark D.

Mayo Clinic

Clinical Transplantation | September 24, 2025 | Volume: 39 | Issue: 10 | Pages: No page available

10.1111/ctr.70329 | PMID 40988593 Get It

ABSTRACT Background Ureteral stents are commonly placed during kidney transplantation (KT) to mitigate urologic complications. The objective of this study was to compare clinical outcomes in KT recipients with either early stent removal when attached to the Foley catheter or late removal via cystoscopy when unattached. Methods We conducted a multi‐center retrospective analysis of consecutive living donor KT patients (8/18/21‐4/21/23) stratified into Foley‐attached and unattached stent groups. Outcomes assessed were ureteral stricture, urine leaks, UTIs at 90 days and allograft failure and BKV DNAemia (BK virus DNAemia) at 1 year. Data are reported as mean and standard deviation. Results Among 247 patients with attached and 260 with unattached stents, baseline demographics (age, sex, diabetes) were similar between groups. There was a difference in race (87.9% vs. 77.8% Caucasian; p = 0.004). Foley catheters remained longer in the attached group (3.7 ± 1.8 vs. 3.0 ± 2.0 days; p < 0.001), but stents were removed earlier (3.7 ± 1.8 vs. 21.9 ± 4.7 days; p < 0.001). Comparing attached versus unattached, there were no differences in ureteral stricture (0.4% vs. 1.5%; p = 0.197), urine leak (0.8% vs. 0.4%; p = 0.533), BKV DNAemia (17.7% vs. 16.9%; p = 0.616), or allograft failure (0% vs. 0.8%; p = 0.167). However, UTI incidence by 90 days was lower in the attached group (5.7% vs. 11.9% p = 0.013). Induction therapy differed significantly between groups, with Alemtuzumab more common in the unattached group (58.1% vs. 19.4%, p < 0.001), Basiliximab more common in the attached group (43.3% vs. 35.0%, p < 0.001), and Thymoglobulin more common in the attached group (36.0% vs. 6.9%, p < 0.001). Baseline steroid use was higher in the unattached group (81.9% vs. 57.9%, p < 0.001). Conclusion Early stent removal via connection to the Foley catheter had similarly low rates of ureteral complications while reducing urinary tract infections and avoiding cystoscopic removal.
A Wearable Multimodal Vital Sign Detection and Photobiomodulation Device for Early Brain Injury Treatment: A Feasibility Study
Kantor, Debbie , Blaivas, Michael , Kantor, Elliot, Greer, Jennifer, Mitra, Kunal , Raj, Mercy Golda Sam, Moore, Caroline , Dong, Yajie , Freeman, William David, Greer, Jennifer, Raj, Mercy Golda Sam, Freeman, William D.

Mayo Clinic

Military Medicine | September 19, 2025 | Volume: 190 | Issue: Supplement_2 | Pages: 387-393

10.1093/milmed/usaf201 | PMID 40984082 Get It

ABSTRACT Traumatic brain injury (TBI), particularly among military personnel, poses significant challenges in acute management and long-term outcomes. Difficult-to-diagnose autoregulatory and inflammatory changes lead to neurocognitive impairment, anxiety, sleep disturbance, and chronic pain. To optimize readiness and test therapeutics for both diagnostic and future TBI treatments, this feasibility study introduces a novel wearable multimodal platform that integrates photoplethysmography and infra-red (IR) sensing from a camera and a wearable sensor to detect vital signs and then leverages machine learning (ML) to predict the need for acute treatment. This prospective observational study involving 28 healthy volunteers simulated a triage emergency room workflow to test sensor accuracy and mobile app functionality. The wearable device demonstrated high accuracy in pulse rate (mean error 7.3%) and oxygen saturation (mean error −1.2%) compared to standard-of-care devices. Camera-based pulse and respiratory rate, and wearable pulse, oxygen, and temperature sensing were tested in a mock triage setting to simulate activation of light-based treatment upon detection of physiological changes of concern after acute TBI. Preliminary ML models to predict hypotension and pain based on retrospective data achieved 98.4% and 93% accuracy but showed limitations in prospective real-time applications. This study provided insights to prepare for future iterations that will integrate near-IR spectroscopy to detect cerebral oximetry, and quantum dot light-emitting diodes to activate light-based treatment (photobiomodulation) from within a wearable head dressing. The findings underscore the potential of this platform to bridge critical gaps in acute TBI care through early detection and future therapeutic intervention. Further development is needed to address environmental challenges, improve accuracy across diverse populations, and refine the device for real-time clinical use. This innovative approach has the potential to revolutionize TBI care by bridging current gaps in diagnostic and therapeutic management.
An Unbiased Cell‐Culture Selection Yields DNA Aptamers as Novel Senescent Cell‐Specific Reagents
Pearson, Keenan , Jachim, Sarah K. , Wilbanks, Brandon , Prieto, Luis I. , Dugan, Maria , LeBrasseur, Nathan K. , Maher, L. James , Pearson, Keenan S , Doherty, Caroline D, Wilbanks, Brandon A, LeBrasseur, Nathan K , III, Louis James Maher , Wilbanks, Brandon A , Doherty, Caroline Lloyd , Baker, Darren J. , Doherty, Caroline

Mayo Clinic

Aging Cell | September 19, 2025 | Volume: 24 | Issue: 11 | Pages: No page available

10.1111/acel.70245 | PMID 40970817 Get It

ABSTRACT Cellular senescence is an irreversible form of cell‐cycle arrest caused by excessive stress or damage. While various biomarkers of cellular senescence have been proposed, there are currently no universal, stand‐alone indicators of this condition. The field largely relies on the combined detection of multiple biomarkers to differentiate senescent cells from non‐senescent cells. Here we introduce a new approach: unbiased cell culture selections to identify senescent cell‐specific folded DNA aptamers from vast libraries of trillions of random 80‐mer DNAs. Senescent mouse adult fibroblasts and their non‐senescent counterparts were employed for selection. We demonstrate aptamer specificity for senescent mouse cells in culture, identify a form of fibronectin as the molecular target of two selected aptamers, show increased aptamer staining in naturally aged mouse tissues, and demonstrate decreased aptamer staining when p16 expressing cells are removed in a transgenic INK‐ATTAC mouse model. This work demonstrates the value of unbiased cell‐based selections to identify new senescence‐specific DNA reagents.
Precision Prevention, Diagnostics, and Treatment of Obesity: Pipedream or Reality?
Woolf, Emily K. , Diktas, Hanim E. , Acosta, Andrés , Apolzan, John W. , Ard, Jamy D. , Boyle, Kristen E. , Katzmarzyk, Peter T. , Nicastro, Holly L. , Redman, Leanne M. , Stephens, Jacqueline M. , Martin, Corby K. , Katzmarzyk, Peter T , Phelan, Suzanne , Redman, Leanne , Roe, Brian E , Stephens, Jacqueline M , Tate, Deborah F , Apovian, Caroline M , Martin, Corby K , Acosta, Andres , Gilbert, Jack A. , Laurienti, Paul J. , Lobstein, Tim , Ordovás, José María , Ryan, Donna H. , Tate, Deborah F.

Mayo Clinic

Obesity | September 18, 2025 | Volume: 33 | Issue: 11 | Pages: 2029-2045

10.1002/oby.70015 | PMID 40964812 Get It

ABSTRACT Precision medicine approaches have gained attention for their potential to more effectively manage obesity by tailoring diagnosis and treatment strategies to individual characteristics, including genetic background, phenotypes, metabolic profiles, and environmental exposures. The current review evaluates the evidence for precision medicine in weight management by summarizing the proceedings of a Pennington Biomedical Scientific Symposium titled “Precision Prevention, Diagnostics, and Treatment of Obesity: Pipedream or Reality?” This review discusses the extent to which we can classify and predict obesity risk based on individual‐level factors; whether we have the diagnostic capability to prospectively identify people who will benefit most from specific interventions; whether prospective trials demonstrate superior prevention and treatment of obesity when precision approaches are applied; and whether evidence is sufficient to guide policy decisions. Expert opinions were presented on the current evidence of precision medicine for obesity to collectively evaluate key barriers and opportunities for implementation of precision approaches in clinical and public health settings.
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis
Ng, Alexander , Asif, Aqua , Gómez‐Gómez, Enrique , Budäus, Lars, Barrett, Tristan , Radtke, Jan Philipp , Kesch, Claudia, Pham, Tho, Tewari, Ash , Cabello, M.A. Rodríguez , Mynderse, Lance A. , Borghi, Marcelo, Boesen, Lars , Singh, Paras B. , Renard‐Penna, Raphaële , Leow, Jeffrey J. , Pecoraro, Martina , Giannarini, Gianluca , Perlis, Nathan , López-Ruiz, Daniel, Rossiter, Marimo , Khetrapal, Pramit , Chan, Vinson Wai‐Shun , Haider, Aiman , Clarke, Caroline S. , Dickinson, Louise , Mitra, Anita, Margolis, Daniel J. A., Takwoingi, Yemisi , Emberton, Mark , Allen, Clare, Moore, Caroline M. , Kasivisvanathan, Veeru , Collaborators, PRIME Study Group, Briganti, Alberto , Evangelista, Alex, Freeman, Alex , Kirkham, Alex, Zlotta, Alexandre R. , Grey, Alistair, Ryan, Andrew, Borrelli, Antonella , Andrews, Antonette, Finelli, Antonio , Sancho, Arturo Platas, Baring, Ashley, Roy, Ashoke, Issa, Balqiisa, Israël, Bas , González, Carolina Aulló, English, Caroline, Zuiani, Chiara , Amate, Cristina, Yong, Daniel , Rozze, Davide, Lomas, Derek J. , Cannoletta, Donato , Chang, Eileen Wang, Chun, Felix, Zussino, Gaia , Antoch, Gerald , Gandaglia, Giorgio, Sauter, Guido , Thevarajah, Harini, Sorrell, Harriet, McBain, Hazel, Reis, Henning , Pita, Hernando Ríos , Potyka, Ingrid , Collavino, Jeanlou, Koshy, Jincy, Weng, Jing Yi , Withington, John, Egmond, Joke van, Piper, Jon, O’Brien, Jonathan , Rosa, José Valero, Sanz, Juan Luis , Quesada, Juan Mesa, Jannusch, Kai , Corr, Kateri , Haines, Kenneth, Umutlu, Lale , Quarta, Leonardo, Casarotto, Letizia, Gimeno, Linda , Moretti, Lucas, Laschena, Ludovica , Drewes, Lukas, Ostos, Manuel Sanchez, Peris, M., Volpacchio, Mariano , Prentice, Mark, Graefen, Markus , Soligo, Matteo, Boschheidgen, Matthias , Singhera, M., Wenzel, Mike, Fatterpekar, Monali, Al‐Nader, Mulham , Kachanov, Mykyta , Shaida, Nadeem , Muirhead, Nicola , Vasdev, Nikhil , Sanmugalingam, Nimalan , Nørgaard, Nis , Vicente, Pete, Incze, Peter , Ryan, Philip, Rouvier, Philippe , Mead, Phoebe, Mozer, Pierre, Viana, Públio César Cavalcante , Jiménez, Rafael E. , Novotta, Réka, Huang, Richard, O’Sullivan, Richard, Jepsen, Rikke Karlin , Frese, Robert, Clow, Rosemary, Al‐Monajjed, Rouvier , Lewis, Sara , Cashman, Sophia, Pizzolitto, Stefano, Lelie, S., Lindner, Sydney, Al‐Hammouri, Tarek , Sánchez, Teresa González, Reid, Thomas, McClure, Timothy, Maurer, Tobias , Peruzzi, Valeria, Tan, Wei Phin, Nahas, William Carlos, Chong, Yew Lam, Agarwal, Ridhi , Panebianco, Valeria , Girometti, Rossano , Ghai, Sangeet , COBELLI, Francesco DE , Pham, Tho, Taneja, Samir S. , Hu, Jim C. , Dias, Adriano Basso , Falkenbach, Fabian , Kastner, Christof , Schimmöller, Lars , Nathan, Arjun , Punwani, Shonit , Brew‐Graves, Chris , Brembilla, Giorgio , Margolis, Daniel , Giganti, Francesco , Collaborators, PRIME Study Group, Crestani, Alessandro , Sciarra, Alessandro , Evangelista, Alex, Kirkham, Alex P. S. , Grey, Alistair, Blanca, Ana , Bjartell, Anders , Tong, Angela , Warren, Anne Y. , Ciardi, Antonio , Rannikko, Antti , Stabile, Armando , Villers, Arnauld A. , Issa, Balqiisa, Hadaschik, Boris Alexander , English, Caroline L, Lee, Chau Hung , Caris, Christien T.M. , Stempel, Conrad von , Rozze, Davide, Messina, Emanuele , Chun, Felix, Gandaglia, Giorgio, Robert, G. , Caglič, Iztok , Theysohn, Jens Matthias , Grummet, Jeremy , Koshy, Jincy, Wilkinson, John, Withington, John, Egmond, Joke van, Deeks, Jonathan J , O'Brien, Jonathan, Quesada, Juan Mesa, Quarta, Leonardo , Orecchia, Luca , Moretti, Lucas, Rooij, Maarten de , Bicchetti, Marco , Gatti, Marco , Peris, María de los Desamparados Esteban, Roethke, Matthias Claudius , Monte, Maurizio Del, Wenzel, Mike, Takahashi, Naoki , Fleshner, Neil , Albers, Peter , Mead, Phoebe, Visschere, Pieter De , Huang, Richard, Shah, Syed Ahmar , Sanchez, Teresa González, Bathala, Tharakeswara K , Kwast, Theodorus van der , Reid, Thomas, Løgager, Vibeke , Prabhu, Vinay , Wagaskar, Vinayak Gorakhnath , Tan, Wei Phin, Nahas, William Carlos, Witjes, Wim P.J. , Chong, Yew Lam, Moore, Caroline

Mayo Clinic

JAMA | September 10, 2025 | Volume: 334 | Issue: 13 | Pages: 1170

10.1001/jama.2025.13722 | PMID 40928788 Get It

Importance Multiparametric magnetic resonance imaging (MRI), with or without prostate biopsy, has become the standard of care for diagnosing clinically significant prostate cancer. Resource capacity limits widespread adoption. Biparametric MRI, which omits the gadolinium contrast sequence, is a shorter and cheaper alternative offering time-saving capacity gains for health systems globally. Objective To assess whether biparametric MRI is noninferior to multiparametric MRI for diagnosis of clinically significant prostate cancer. Design, Setting, and Participants A prospective, multicenter, within-patient, noninferiority trial of biopsy-naive men from 22 centers (12 countries) with clinical suspicion of prostate cancer (elevated prostate-specific antigen [PSA] level and/or abnormal digital rectal examination findings) from April 2022 to September 2023, with the last follow-up conducted on December 3, 2024. Interventions Participants underwent multiparametric MRI, comprising T2-weighted, diffusion-weighted, and dynamic contrast–enhanced (DCE) sequences. Radiologists reported abbreviated biparametric MRI first (T2-weighted and diffusion-weighted), blinded to the DCE sequence. After unblinding, radiologists reported the full multiparametric MRI. Patients underwent a targeted biopsy with or without systematic biopsy if either biparametric MRI or multiparametric MRI was suggestive of clinically significant prostate cancer. Main outcomes and measures The primary outcome was the proportion of men with clinically significant prostate cancer. Secondary outcomes included the proportion of men with clinically insignificant cancer. The noninferiority margin was 5%. Results Of 555 men recruited, 490 were included for primary outcome analysis. Median age was 65 (IQR, 59-70) years and median PSA level was 5.6 (IQR, 4.4-8.0) ng/mL. The proportion of patients with abnormal digital rectal examination findings was 12.7%. Biparametric MRI was noninferior to multiparametric MRI, detecting clinically significant prostate cancer in 143 of 490 men (29.2%), compared with 145 of 490 men (29.6%) (difference, −0.4 [95% CI, −1.2 to 0.4] percentage points; P = .50). Biparametric MRI detected clinically insignificant cancer in 45 of 490 men (9.2%), compared with 47 of 490 men (9.6%) with the use of multiparametric MRI (difference, −0.4 [95% CI, −1.2 to 0.4] percentage points). Central quality control demonstrated that 99% of scans were of adequate diagnostic quality. Conclusion and relevance In men with suspected prostate cancer, provided image quality is adequate, an abbreviated biparametric MRI scan, with or without targeted biopsy, could become the new standard of care for prostate cancer diagnosis. With approximately 4 million prostate MRIs performed globally annually, adopting biparametric MRI could substantially increase scanner throughput and reduce costs worldwide. Trial registration ClinicalTrials.gov Identifier: NCT04571840
Genetic risk factors modulate the association between physical activity and colorectal cancer
Kim, Andre E., Fu, Yubo, Morrison, John, Lin, Yi, Berndt, Sonja, Chang-Claude, Jenny, Conti, David V., Corley, Douglas A. , Gruber, Stephen B. , Harlid, Sophia , Huyghe, Jeroen R. , Kundaje, Anshul , Martín, Vicente , Newton, Christina C. , Hardikar, Sheetal , Pai, Rish K. , Papadimitriou, Nikos , Pinchev, Mila, Schoen, Robert , Tsilidis, Konstantinos K, Duijnhoven, Franzel J. B. van, Visvanathan, Kala , Wolk, Alicja, Woods, Michael O. , Wu, Anna H. , Ulrich, Cornelia M. , Peters, Ulrike, Gauderman, W. James, Moreno, Victor, Martín, Vicente , Drew, David A. , Martín, Vicente , Drew, David A , Visvanathan, Kala , Kundaje, Anshul , Papadimitriou, Nikos , Peoples, Anita R , Obón‐Santacana, Mireia , Kawaguchi, Eric , Qu, Conghui , Moratalla-Navarro, Ferrán , Morrison, John, Arndt, Volker , Bien, Stephanie A. , Bishop, D. Timothy , Bouras, Emmanouil , Brenner, Hermann , Buchanan, Daniel D. , Campbell, Peter T. , Chan, Andrew T. , Chang‐Claude, Jenny , Conti, David V. , Devall, Matthew A M , Dimou, Niki , Gunter, Marc J. , Harrison, Tabitha A. , Hoffmeister, Michael , Hsu, Li , Keku, Temitope O , Lewinger, Juan Pablo , Lynch, Brigid M , Marchand, Loı̈c Le , Murphy, Neil , Ogino, Shuji , Ose, Jennifer , Palmer, Julie R. , Pardamean, Bens , Pellatt, Andrew J. , Platz, Elizabeth A. , Potter, John D. , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C. , Schoen, Robert E., Shcherbina, Anna, Stern, Mariana Carla , Su, Yu-Ru , Thomas, Claire E. , Tian, Yu , Tsilidis, Konstantinos K. , Um, Caroline Y. , Guelpen, Bethany Van , Wang, Jun, White, Emily , Wolk, Alicja , Peters, Ulrike, Gauderman, W. James

Mayo Clinic

No container title available | September 2, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7350654/v1 | PMID 40951278 Get It

Abstract Background Physical activity (PA) is an established protective factor for colorectal cancer (CRC), but it is unclear if genetic variants modify this effect. To investigate this possibility, we conducted a genome-wide gene–PA interaction analysis. Methods Using logistic regression and two-step and joint tests, we analyzed interactions between common genetic variants across the genome and PA in relation to CRC risk. Self-reported PA levels were categorized as active (≥ 8.75 MET-h/wk) vs. inactive (< 8.75 MET-h/wk) and as study- and sex-specific quartiles of activity. Results PA had an overall protective effect on CRC (OR [active vs. inactive] = 0.85; 95%CI = 0.81–0.90). The two-step GxE method identified an interaction between rs4779584, an intergenic variant near the GREM1 and SCG5 genes, and PA for CRC risk (p-interaction = 2.6×10 − 8 ). Stratification by genotype at this locus showed a significant reduction in CRC risk by 20% in active vs. inactive participants with the CC genotype (OR = 0.80; 95%CI = 0.75–0.85), but no significant PA–CRC association among CT or TT carriers. When PA was modeled as quartiles, the 1-d.f. GxE test identified that rs56906466, an intergenic variant near the KCNG1 gene, modified the association between PA and CRC (p-interaction = 3.5×10 − 8 ). Stratification at this locus showed that increase in PA (highest vs. lowest quartile) was associated with a lower CRC risk solely among TT carriers (OR = 0.77; 95%CI = 0.72–0.82). Conclusions In summary, we identified two genetic variants that modified the association between PA and CRC risk. One of them, related to GREM1 and SCG5 , suggests that the bone morphogenetic protein (BMP)-related, inflammatory, and/or insulin signaling pathways may be associated with the protective influence of PA on colorectal carcinogenesis.